EDE Dengue monoclonal antibodies
Clinical ready human monoclonal antibodies that target the Envelope Dimer Epitope on dengue virions, enabling cross-serotype neutralisation from a single conserved site and deployable IgG/fragment formats for passive immunisation.
Applications: Post-exposure therapy, Pre-exposure prophylaxis, Outbreak ring prophylaxis, High-risk healthcare exposure, Serotype-agnostic treatment, Reference assay standards, Emergency stockpiles
| Features | Benefits |
|---|---|
| Demonstrated broad neutralisation of dengue virions produced in insect and human cells | Single-antibody approach supports cross-serotype coverage |
| Two antibody classes (EDE1/EDE2) with distinct breadth profiles characterised in vitro | Streamlines development by focusing on a conserved dimer epitope |
| Reported therapeutic activity of EDE antibodies against Zika in preclinical studies | Suitable for prophylactic or therapeutic passive immunization use cases |
| Compatible with multiple molecular formats (full IgG and fragments) | Enables consistent antigen/assay alignment around the E-dimer epitope |
| Epitope definition and assays anchored to native virion quaternary structure | Supported by breadth across diverse clinical strains in cell-based assays |
| Binds a quaternary epitope spanning the E-protein dimer interface across DENV-1–4 | Potential spill over utility against related flaviviruses (e.g., Zika) |
| Clinical-ready asset with first-in-human trial planned |